Big Moving Stock keep track of the biggest moving stocks in the market.


Nasdaq: GOOG NFLX BIIB AMZN IBB TSLA WYNN ILMN ALXN GMCR AMGN SLXP COST CNQR SBAC VRTX GILD AAPL MNST
Nyse: ACT V LNKD IVV AGN PXD GS LMT SPG IBM FDX MMM TWC CMI HUM APD PX GD NOC BDX
New Highs: REGN SHW ILMN PSA SPG ORLY GMCR AAP COST GILD AAPL HAIN RTN TRV CELG HD GPC NKE UNH CVS

The Hot Industries

Biotechnology 4
Auto Parts Stores 2
Auto Parts Wholesale 1

The Hot Sectors

Services 7
Healthcare 5
Consumer Goods 3

TNX Stock Chart

TNX

favicon

TKMR Stays Focused On Ebola, GEVA Sets Work Rolling, FDA Panel Nod For VRTX

21 Oct 2014, 10:35 pmThe FDA's Pulmonary Allergy Drugs Advisory Committee has voted 13-2 to recommend approval of Vertex Pharmaceuticals Inc.'s cystic fibrosis drug KALYDECO for expanded use in people with cystic fibrosis ages 6 and older who have the R117H mutation in the cystic fibrosis transmembrane regulatory (CFTR) gene.
favicon

Tonix Pharma Gets IND Clearance For TNX-201 In Episodic Tension-Type Headache

21 Oct 2014, 7:18 amTonix Pharma Gets IND Clearance For TNX-201 In Episodic Tension-Type Headache
favicon

Volatility, Stock Headwinds Create Alternative Fund Opportunity

7 Oct 2014, 1:43 pmNEW YORK (TheStreet) -- After bursting through the 2,000 level, the S&P 500 has had trouble garnering much upside action over the past several weeks as volatility continues to heat up.a But according to Brian Jacobsen, chief portfolio strategist at Wells Fargo Funds Management, that increased volatility is a positive for actively managed alternative funds.a Must Read: Warren Buffett's Top 10 ...
favicon

Stock Market Top -Bear Market begins

2 Oct 2014, 1:13 pmThe DOW was in an Ending Diagonal pattern which we have followed for many months before the recent downside. The chart below is from our members page and illustrates the completed pattern on Sept 23rd indicating a stock market top.
favicon

Tonix Pharmaceuticals Holding (TNXP) Sank To A 10-Month Low After Study Failed

30 Sep 2014, 5:49 amTonix Pharmaceuticals Holding (TNXP) announced Monday morning that its Phase 2b BESTFIT study of TNX-102 SL as a chronic bedtime treatment for fibromyalgia, did not achieve statistical significance in the primary efficacy endpoint of change in average daily pain score at week 12.
favicon

TNXP: Tonix reports results from the Phase 2b/3 BESTFIT trial

29 Sep 2014, 5:00 pmOn September 29, 2014, Tonix Pharmaceuticals (TNXP) announced top line results for the Phase 2b/3 BESTFIT trial. The study did not achieve statistical significance in the primary efficacy endpoint of change in average daily pain score at week 12 (p=0.086 by mixed-effect model repeated measure analysis, p=0.172 by jump-to-control, multiple imputation analysis). Below we will briefly review the ...
favicon

Why Tonix Pharmaceuticals (TNXP) Stock Is Plummeting Today

29 Sep 2014, 1:58 pmNEW YORK (TheStreet) -- Shares ofaTonix Pharmaceuticalsa plummeted 49.43% to $7.06 on Monday after the company announced its lead drug candidate for treating fibromyalgia came up short ofathe primary goal in a mid-stage trial. Tonix'sadrug TNX-102 missed the mark in the study, which tested if the drug reduced patients' pain by the 12th week of the trial. TNX-102 did, however,aimprove sleep ...
favicon

Sector Update: Health Care

29 Sep 2014, 12:40 pmSector Update: Health Care
favicon

Tonix Pharma's pain drug fails mid-stage study

29 Sep 2014, 8:45 amTonix Pharmaceuticals Holding Corp said its lead drug for pain management failed the main goal of a mid-stage study, sending its down by more than half in early trading. The drug, TNX-102, is being tested to treat fibromyalgia, a chronic syndrome characterized by widespread pain and lack of sleep. The treatment failed the main goal of reducing pain experienced by patients by the 12th week of the ...
favicon

Tonix Pharmaceuticals Holding (TNXP) Is Sinking After Phase 2 Study Failed

29 Sep 2014, 8:12 amTonix Pharmaceuticals Holding (TNXP) announced Monday morning that its Phase 2b BESTFIT study of TNX-102 SL as a chronic bedtime treatment for fibromyalgia, did not achieve statistical significance in the primary efficacy endpoint of change in average daily pain score at week 12.